← All trials
NCT02195232
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Aug 1, 2018
- Completion date
- Apr 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 618
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Quercegen PharmaceuticalsCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.